A first quarter review of our company shows amazing progress;
1. Approval of the pivotal study with 20 patients
2. Agreement on performance criterion for the pivotal study
3. Acceptance of modular submission of pivotal study results
4. Enrolment of two new patients
5. 5 Additional treatment sites in the U.S.
6. AIS Improvement of Patient 5
7. Secured financing way until commercialization
This is really an incredible pace and one has to congratulate management of NVIV for such extraordinary results.
It is a shame that the investment community has not (yet) realized or understood the real value of InVivo (maybe except the investors from the latest financing round). The current share price is completely disconnected from NVIV’s business value and does not mirror the excellent position of risk versus reward. The company value of roughly 200 m is a joke, especially if you factor in the current cash position of 50 m (200 m minus 50 m in cash)! NVIV has not some kind of obscure drug or device that will be on the market in 5 to 10 years if everything goes well. Not at all! We are taking giant steps towards commercialization for a product without competition and a few hundred million of revenues in the first two years alone. The NSS product can be on the market as early as in 12 to 15 months and the risk that the FDA will not approve the NSS is very, very marginal.
This is not the first company which is significantly undervalued for quite some time. However it is unavoidable that such extreme misvalue will always be corrected by Mister Market himself. We are very close and only need a little more patience, maybe to summer, but then we will see some explosive corrections into the 20ies, 30ies or much higher. At the end value prevails over manipulation.